NVP-AEW541

For research use only.

Catalog No.S1034 Synonyms: AEW541

42 publications

NVP-AEW541 Chemical Structure

Molecular Weight(MW): 439.55

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 414 In stock
USD 210 In stock
USD 370 In stock
USD 670 In stock
USD 2217 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's NVP-AEW541 has been cited by 42 publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
Targets
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
Tek [1]
(Cell-free assay)
FLT1 [1]
(Cell-free assay)
0.14 μM 0.15 μM 0.42 μM 0.53 μM 0.6 μM
In vitro

NVP-AEW541 also inhibits InsR, Tek, Flt1 and Flt3 with IC50 of 140 nM, 530 nM, 600 nM and 420 nM in purified kinases/recombinant kinase domains assay. NVP-AEW541 is more selective and shows 27-fold more potent than InsR at the cellular level. NVP-AEW541 suppresses the IGF-I-mediated survival, soft agar and proliferation of MCF-7 cells with IC50 of 0.162 μM, 0.105 μM and 1.64 μM, respectively. NVP-AEW541 also reduces the level of phospho-IGF-1R and phospho-PKB in NWT-21 cells. [1] NVP-AEW541 shows growth inhibitory effect on TC-71 musculoskeletal sarcoma cells in low-serum medium as well as in 10% FBS–containing medium. NVP-AEW541 inhibits cell cycle progression and induces specific G1 arrest in sarcoma cell lines (TC-71, SK-N-MC, SaoS-2, RD/18 and RH4). [2] NVP-AEW541 could inhibit the growth of human neuroblastoma cells with IC50 of 0.4-6.8 μM. An increase in the hypodiploid fraction and the depletion of the S and G2-M compartments could be detected in these cell lines. NVP-AEW541-driven inhibition of IGF-1R causes a reduction of phosphorylation of Akt, but not of Erk1 and Erk2 in neuroblastoma cells. [3] NVP-AEW541 inhibits glioma cell growth and disrupts the autocrine loop initiated by HIF1α stabilization. [4] A recent study shows that NVP-AEW541 suppresses the proliferation and viability of PC3, DU145, and 22Rv1 prostate cancer cells, without necessarity of associated cell death. NVP-AEW541 decreases phospho-Akt levels in 22Rv1 and DU415 cells but not PC3 cells, without affecting total Akt levels, which shows that PTEN status could determine the effectiveness of NVP-AEW541 with essential Akt. NVP-AEW541-induced radiosensization is dependent on Akt activation status. NVP-AEW541 could increase the H2AX phosphorylation (a measure of DSBs) in PC3, DU145, and 22Rv1 cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NWT-21 M2jMTGtqdmG|ZTDhd5NigQ>? NUHRNWZDhjFy4pEK{txO NVn1bWlCTE2VTx?= MXzpcohq[mm2czDJS2YuUVJid3n0bEBKSzVyIH;mJFAvODh4INMxJFAvODJ6IN88US=> NHPxUmMyPTB3MEmxOS=>
A14 NYDGUnBiU2mwYYPlJIF{e2G7 MX;+NVDjiIsQvF2= M1rYNWROW09? M13xOYlvcGmkaYTzJGlve1Jid3n0bEBKSzVyIH;mJFIvOyEEsTCwMlE3OyEQvF2= M4[0fFE2ODVyOUG1
A431  M2LmPGtqdmG|ZTDhd5NigQ>? MnjxglEx6oDMzszN Mn[ySG1UVw>? Ml7TbY5pcWKrdIOgTGVTOSC5aYToJGlEPTBib3[gQlExKM7:TR?= NVKyOGFwOTVyNUC5NVU>
A31  MWnLbY5ie2ViYYPzZZk> MXT+NVDjiIsQvF2= NFrHUJFFVVOR MlXCbY5pcWKrdIOgVGRITlJid3n0bEBKSzVyIH;mJF4yOCEQvF2= MUixOVA2ODlzNR?=
GIST882 NWn6dppNU2mwYYPlJIF{e2G7 M3jOU54yOOLCit88US=> MW\EUXNQ MWnpcohq[mm2czDjMWtqfCC5aYToJGlEPTBib3[gQlUh|ryP NInUcpEyPTB3MEmxOS=>
32D-Bcr-Abl M3rzWmtqdmG|ZTDhd5NigQ>? NYjYbnhzhjFy4pEK{txO NInRXmtFVVOR NILm[nhqdmirYnn0d{BD[3JvQXLsJJAzOTBid3n0bEBKSzVyIH;mJF4yOCEQvF2= NGm1UnIyPTB3MEmxOS=>
MCF-7  M1v0emN6fG:6aXPpeJkh[XO|YYm= MWPEUXNQ MYnJR|UxRTFwNkSg{txO MnPMNVUxPTB7MUW=
NWT-21 M37WcWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYTEUXNQ NVLCOGFTUUN3ME2wMlE3OyEQvF2= MVexOVA2ODlzNR?=
TC-71 NHfpdnNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHvubFR,OSEQvF2= M2r5[mROW09? MYTpcohq[mm2czDpcpN2dGmwLXzpb4Uh\3Kxd4ToJIZi[3Sxcj3J5qCUdWWmaXH0[YQh\3Kxd4To M4DMeVE2QDZ5M{i2
TC-71 NVPteVRyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYH+O-KBks7:TR?= MlK2SG1UVw>? NYLiXFVXUUN3MEywMlUh|ryP M3joN|E2QDZ5M{i2
Saos-2 MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmLLglfjiIsQvF2= Ml3KSG1UVw>? MVPJR|UxRDNizszN M3TRSFE2QDZ5M{i2
U-2OS NETEcHVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnPIglfjiIsQvF2= M3vhT2ROW09? NVnWVlRZUUN3MEywMlUh|ryP MkjLNVU5Pjd|OE[=
SK-ES-1 M3vTVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUT+O-KBks7:TR?= NEXJXmFFVVOR MXvJR|UxRDBwNTFOwG0> MXexOVg3PzN6Nh?=
SK-N-MC M1zpZ2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYnP[3NWhjgkgJtOwG0> MUfEUXNQ NXr0d48yUUN3MEywMlUh|ryP NWfnZm4yOTV6NkezPFY>
RD-ES MmTMS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYrOdWxDhjgkgJtOwG0> NHHpW3dFVVOR MVvJR|UxRDBwNTFOwG0> NGP5NVQyPTh4N{O4Oi=>
SJ-Rh 30 MoXjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MY\+O-KBks7:TR?= M4[xS2ROW09? MV\JR|UxRDBwNTFOwG0> MlfsNVU5Pjd|OE[=
SJ-Rh 4 Mn;QS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYH+O-KBks7:TR?= NH72ZlhFVVOR MmLKTWM2ODxyLkWg{txO NGTwOJQyPTh4N{O4Oi=>
6647 NYLkdG1zT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGfScmR,P+LCit88US=> NXX0O3Z3TE2VTx?= M2e2dmlEPTB:MD61JO69VQ>? M2PPZlE2QDZ5M{i2
SARG MlvoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUDnbIh{hjgkgJtOwG0> NGS4clBFVVOR M2XIWmlEPTB:MzFOwG0> MkexNVU5Pjd|OE[=
MOS MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4Cxep446oDMzszN M1exSGROW09? NEjuToNKSzVyPESg{txO MknXNVU5Pjd|OE[=
IOR/OS7 M4DYdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUX+O-KBks7:TR?= MUfEUXNQ Mn7JTWM2ODxzIN88US=> NVy3SFNJOTV6NkezPFY>
IOR/OS9 NH23eVBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXfXVJRLhjgkgJtOwG0> M3XJc2ROW09? NUXKc3NEUUN3MEy2JO69VQ>? M3GzUlE2QDZ5M{i2
IOR/OS10 NWS2XZI6T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXXOS2k{hjgkgJtOwG0> MmjmSG1UVw>? M1jFc2lEPTB:NTFOwG0> MmXaNVU5Pjd|OE[=
IOR/OS14 MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIrPUVJ,P+LCit88US=> Mor4SG1UVw>? NEC5O4JKSzVyPESg{txO NGr0N3cyPTh4N{O4Oi=>
LAP35 NYC4XoVwT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYj+O-KBks7:TR?= Ml[1SG1UVw>? NVTzXVZmUUN3MEywMlUh|ryP MlzONVU5Pjd|OE[=
IOR/BRZ NEjjXmhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFrsXW5,P+LCit88US=> MnHHSG1UVw>? M3vmfWlEPTB:MD61JO69VQ>? NHPQOIIyPTh4N{O4Oi=>
IOR/CAR M3;rOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWq4TItKhjgkgJtOwG0> MX7EUXNQ MVzJR|UxRDFizszN MVSxOVg3PzN6Nh?=
IOR/NGR MmHsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXj+O-KBks7:TR?= NXz6cpM3TE2VTx?= NVfLb2ZpUUN3MEywMlUh|ryP NFPQNnQyPTh4N{O4Oi=>
IOR/RCH Ml3iS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3rjUp446oDMzszN NF7WbFhFVVOR MkjGTWM2ODxyLkWg{txO NWjofo5XOTV6NkezPFY>
RMZ-RC2 MnvBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1vpbp446oDMzszN NV76Z|hjTE2VTx?= NVLvT29tUUN3MEywMlUh|ryP Ml;oNVU5Pjd|OE[=
CCA M2TITWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXfLPVNshjgkgJtOwG0> MofCSG1UVw>? M2PKUGlEPTB:MjFOwG0> MWKxOVg3PzN6Nh?=
RD/18 NGTnR|JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXn+O-KBks7:TR?= M{jidGROW09? M33wPWlEPTB:NDFOwG0> Mm\XNVU5Pjd|OE[=
OVCAR-3 NVq3OHVlT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYDsXXZwhjF34pEK{txO NX\EWG1uTE2VTx?= NWfuNJZQcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v M1\QdlE3OzByOEKw
OVCAR-4 MmfxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnnXglE26oDMzszN MWDEUXNQ MYPpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= MlTvNVY{ODB6MkC=
OVCAR-3 NIHW[3FCeG:ydH;zbZMh[XO|YYm= MWT+NVXjiIsQvF2= M3vseWROW09? NVzER29UcW6mdXPld{BieG:ydH;zbZM> NHf2V4EyPjNyMEiyNC=>
OVCAR-4 M2r5[WFxd3C2b4Ppd{Bie3OjeR?= MVv+NVXjiIsQvF2= MojOSG1UVw>? NIP0coRqdmS3Y3XzJIFxd3C2b4Ppdy=> NGrNN2EyPjNyMEiyNC=>
OVCAR-3 NHnYUGVHfW6ldHnvckBie3OjeR?= MoPXglE26oDMzszN NEG5eFFFVVOR NEfxcnVF\WO{ZXHz[ZMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= M3HG[FE3OzByOEKw
Huh-7 MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M37nOJ4yOOLCit88US=> NEPoSWJFVVOR M{LNU2lEPTB;MT60JO69VQ>? MUWxOlU{ODd|NB?=
Hep-G2 MnrvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MkTUglEx6oDMzszN Mor1SG1UVw>? MnvHTWM2OD1zLkig{txO NVvZUFl4OTZ3M{C3N|Q>
Hep-3B NH;TbndIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoTpglEx6oDMzszN NEGyZ4VFVVOR MoDrTWM2OD1zLkmg{txO MlvQNVY2OzB5M{S=
SK-Hep-1 NUfTR3A6T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnjjglEx6oDMzszN NYnPWmNyTE2VTx?= MXfJR|UxRTZwOTFOwG0> NW\xW4VKOTZ3M{C3N|Q>
Huh-7 M4XtN2Z2dmO2aX;uJIF{e2G7 Mn:xglEx6oDMzszN NIfQ[IxFVVOR Mm\GTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NI\pTVUyPjV|MEezOC=>
Hep-G2 MlTuSpVv[3Srb36gZZN{[Xl? MXr+NVDjiIsQvF2= NFTRO4JFVVOR MXTJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NXLJUZF3OTZ3M{C3N|Q>
SK-Hep-1 MkXLSpVv[3Srb36gZZN{[Xl? MlvQglEx6oDMzszN MlHPSG1UVw>? NYLuW49IUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MUmxOlU{ODd|NB?=
BON NHv4W5dMcW6jc3WgZZN{[Xl? Mm\PglYh|ryP MWHEUXNQ MnjVbY5lfWOnczDk[ZBpd3OyaH;yfYxifGmxbjDv[kBKT0ZvMWK= NWq5eIpxOTZ4MEGyPFQ>
BON NYLkc2JRT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4fBc54yOOLCit88US=> M3LkfWROW09? M4Do[mlEPTB;Nj62JO69VQ>? MYCxOlYxOTJ6NB?=
CM NVXNdldIT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGTqbXh,PeLCit88US=> MUjEUXNQ NWD2TodUUUN3ME2zMlMh|ryP Ml3pNVY3ODF{OES=
BON M2jDW2Z2dmO2aX;uJIF{e2G7 MVf+O{426oDMzszN NWPQWnF2TE2VTx?= MYLpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NYLVWow2OTZ4MEGyPFQ>
CM MYrGeY5kfGmxbjDhd5NigQ>? MX;+OgKBks7:TR?= NXjhV4tiTE2VTx?= NYPvcppYcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NVfEepFwOTZ4MEGyPFQ>
BON NWHj[HBPSXCxcITvd4l{KGG|c3H5 MWX+O{426oDMzszN NEDCZWFFVVOR NW[0U4NjcW6mdXPld{BCeG:ydH;zbZM> NF;1UI8yPjZyMUK4OC=>
CM M{GxN2Fxd3C2b4Ppd{Bie3OjeR?= Mn:yglXjiIsQvF2= M3[xdWROW09? MUXpcoR2[2W|IFHwc5B1d3Orcx?= MWSxOlYxOTJ6NB?=
HT-29 M{LpU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYL+NVDjiIsQvF2= MVHEUXNQ NID3cXhKSzVyPUGuO{DPxE1? MoXINVcxODdyMUW=
HCT-116 NYXOXpI6T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2D5PJ4yOOLCit88US=> MWfEUXNQ NUT2XGs3UUN3ME2yMlUh|ryP MnTPNVcxODdyMUW=
primary colorectal cancer cells NU\vOnF3TnWwY4Tpc44h[XO|YYm= Mon5glXjiIsQvF2= NWPqboM4TE2VTx?= NEG0Oo9idHSncoOgeIhmKG2xcoDoc4xw\3lib3[geIhmKHKnbXHpcolv\yClZXzsdy=> NILHXlUyPzByN{CxOS=>
HTLA-230 MWLGeY5kfGmxbjDhd5NigQ>? NWfVUJhNhjhizszN NFW0[4RFVVOR NHm0OlJqdmirYnn0d{BKT0ZvSVmtcYVlcWG2ZXSgd5RqdXWuYYTpc44hd2ZiSVfGMWlTKGGwZDDBb5Q> MnHPNVcyOjF6OUi=
KCNR MWXGeY5kfGmxbjDhd5NigQ>? Mk\Bglgh|ryP NInzZ2JFVVOR M4W5bolvcGmkaYTzJGlITi2LST3t[YRq[XSnZDDzeIlufWyjdHnvckBw\iCLR1[tTXIh[W6mIFHreC=> NFuycYsyPzF{MUi5PC=>
SK-N-BE2c NXq3[5NwTnWwY4Tpc44h[XO|YYm= MlW5glgh|ryP M1;KPGROW09? MoXjbY5pcWKrdIOgTWdHNUmLLX3l[IlifGWmIIP0bY12dGG2aX;uJI9nKEmJRj3JVkBidmRiQXv0 NWPBd45wOTdzMkG4PVg>
SK-N-BE MYLGeY5kfGmxbjDhd5NigQ>? Mn6xglgh|ryP MlrISG1UVw>? MU\pcohq[mm2czDJS2YuUUlvbXXkbYF1\WRic4TpcZVt[XSrb36gc4YhUUeILVnSJIFv\CCDa4S= MUCxO|EzOTh7OB?=
LAN-5 MoTTSpVv[3Srb36gZZN{[Xl? M1;nXp45KM7:TR?= M2nsbmROW09? MlLsbY5pcWKrdIOgTWdHNUmLLX3l[IlifGWmIIP0bY12dGG2aX;uJI9nKEmJRj3JVkBidmRiQXv0 MXixO|EzOTh7OB?=
GI-CA-N MYHGeY5kfGmxbjDhd5NigQ>? NYP3Npg6hjhizszN MnS5SG1UVw>? MlzLbY5pcWKrdIOgTWdHNUmLLX3l[IlifGWmIIP0bY12dGG2aX;uJI9nKEmJRj3JVkBidmRiQXv0 NVntO5JROTdzMkG4PVg>
SH-EP NVfHeWxWTnWwY4Tpc44h[XO|YYm= MUL+PEDPxE1? MXLEUXNQ NIXv[nBqdmirYnn0d{BKT0ZvSVmtcYVlcWG2ZXSgd5RqdXWuYYTpc44hd2ZiSVfGMWlTKGGwZDDBb5Q> M320O|E4OTJzOEm4
SK-N-AS M{HGWGZ2dmO2aX;uJIF{e2G7 MnX2glgh|ryP MUTEUXNQ NEHPSFFqdmirYnn0d{BKT0ZvSVmtcYVlcWG2ZXSgd5RqdXWuYYTpc44hd2ZiSVfGMWlTKGGwZDDBb5Q> NHfPWogyPzF{MUi5PC=>
RN-GA NGHEWVNHfW6ldHnvckBie3OjeR?= Mm\Mglgh|ryP NUS3RXNrTE2VTx?= MkDsbY5pcWKrdIOgTWdHNUmLLX3l[IlifGWmIIP0bY12dGG2aX;uJI9nKEmJRj3JVkBidmRiQXv0 NXXVTlA4OTdzMkG4PVg>
SY-5Y(N) NFXSOXNHfW6ldHnvckBie3OjeR?= Mnqyglgh|ryP NXLiUGtJTE2VTx?= MoHmbY5pcWKrdIOgTWdHNUmLLX3l[IlifGWmIIP0bY12dGG2aX;uJI9nKEmJRj3JVkBidmRiQXv0 M2DMXVE4OTJzOEm4
GI-CA-N M1LZUWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHfnXo1,QCEQvF2= M3LiTGROW09? NVvpeW9XUUN3ME2gOk45KM7:TR?= NVfidXUyOTdzMkG4PVg>
SH-EP NWTxfZN[T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoHjglgh|ryP NWq0OJdHTE2VTx?= NIDBXotKSzVyPTCzJO69VQ>? Mlj0NVcyOjF6OUi=
HTLA-230 M{[1VGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NX\hU4hRhjhizszN MkP0SG1UVw>? MYTJR|UxRSByLkWg{txO NEDGSJgyPzF{MUi5PC=>
SK-N-BE2c MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NH:ye2J,QCEQvF2= MkPkSG1UVw>? MUTJR|UxRSBzLkGg{txO M1HU[FE4OTJzOEm4
SK-N-BE2 M3nIVmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVT+PEDPxE1? Mlu0SG1UVw>? NH63bIFKSzVyPTCzJO69VQ>? M4nxTVE4OTJzOEm4
SY-5Y (N) NUe4PY81T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVH+PEDPxE1? MUnEUXNQ MUfJR|UxRSB{LkSg{txO MWqxO|EzOTh7OB?=
LAN-5 NYPRZ|ZiT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVr+PEDPxE1? NGn4TZJFVVOR MlnzTWM2OD1iMD60JO69VQ>? MXOxO|EzOTh7OB?=
KCNR NYHtc|VbT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUnUUod1hjhizszN M2O5Z2ROW09? NUW4SJljUUN3ME2gNE41KM7:TR?= NILjfpgyPzF{MUi5PC=>
RN-GA NFv1[|VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUX+PEDPxE1? NIrwdoZFVVOR NHH6OFRKSzVyPTCxMlMh|ryP MVmxO|EzOTh7OB?=
SK-N-AS NHvjfmpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWr+PEDPxE1? MX3EUXNQ MUXpcoR2[2W|IHHwc5B1d3Orcx?= NITNeJkyPzF{MUi5PC=>
KCNR Mof4RZBweHSxc3nzJIF{e2G7 NEPHXJV,QCEQvF2= MYrEUXNQ MULpcoR2[2W|IHHwc5B1d3Orcx?= M2PGW|E4OTJzOEm4
GI-CA-N MlPvRZBweHSxc3nzJIF{e2G7 Mmrtglgh|ryP M{\sNGROW09? NGLXWlJqdmS3Y3XzJIFxd3C2b4Ppdy=> NULaZW1SOTdzMkG4PVg>
HTLA-230 NGK0e41CeG:ydH;zbZMh[XO|YYm= M4\0e545KM7:TR?= MlvOSG1UVw>? MoG2bY5lfWOnczDhdI9xfG:|aYO= MnfrNVcyOjF6OUi=
SK-N-BE2c NWnkXok{SXCxcITvd4l{KGG|c3H5 NVXoe5BohjhizszN NH:5d3FFVVOR NYjHcYE3cW6mdXPld{BieG:ydH;zbZM> NFrQSZgyPzF{MUi5PC=>
SY-5Y (N) MmjjRZBweHSxc3nzJIF{e2G7 M3nyVp45KM7:TR?= NWPGXYhvTE2VTx?= M{LKU4lv\HWlZYOgZZBweHSxc3nz MUmxO|EzOTh7OB?=
HL60AR M4fBe2Z2dmO2aX;uJIF{e2G7 NHv6T4syPjBibl2= NFTZO2hmdmijbnPld{B1cGVibHX2[Yx{KG:oIICyO2tqeDF? M4njNVE4OzZzMkK1
HL60AR MmLhRZBweHSxc3nzJIF{e2G7 NWHOWGdIhjJyMDDuUS=> NEDSWpZqdmS3Y3XzJIFxd3C2b4Ppdy=> NW\HcXFIOTd|NkGyNlU>
HPAF-II NETVN5VMcW6jc3WgZZN{[Xl? NIjLTYJ,OSEQvF2= Mo[1SG1UVw>? M3KyTYlvcGmkaYTzJGlITi2LLX3l[IlifGWmIIPp[45idGyrbne= MnfTNVg1PDV3MkC=
HPAF-II M3G3NGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NEnJNmJ,OiEQvF2= NF7Ud4lFVVOR M{DZS4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> Mmn1NVg1PDV3MkC=
HPAF-II MUPGeY5kfGmxbjDhd5NigQ>? MYf+NkDPxE1? M1nIfGROW09? NVH1b4h[cW6qaXLpeJMh[mG|YXygZY5lKEmJRj3JMY1m\GmjdHXkJJBidmO{ZXH0bYMh[2GwY3XyJINmdGxibXnndoF1cW:w MWCxPFQ1PTV{MB?=
TFK-1 M2rmUmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUT4SVlkhjJ3MDDuUS=> M{fkRWROW09? M13B[2lEPTB;MD6yOkDPxE1? M3K3R|IxODZ4N{O0
EGI-1 MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2nKdJ4zPTBibl2= M2ni[WROW09? MVTJR|UxRTBwMkig{txO M{i5OVIxODZ4N{O0
CC-LP-1 MmjlS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGCyW3J,OjVyIH7N MVPEUXNQ MYXJR|UxRTBwMUWg{txO NV;Kd5ZyOjByNk[3N|Q>
CC-SW-1 M3\3Rmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYn+NlUxKG6P NV3sOpdlTE2VTx?= M{XWOWlEPTB;MD61OEDPxE1? MW[yNFA3Pjd|NB?=
Sk-ChA-1 MlH6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHTzd4l,OjVyIH7N NFfpe5pFVVOR NVToPW04UUN3ME2wMlIh|ryP M1n0c|IxODZ4N{O0
Mz-ChA-1 M{H3bGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmTxglI2OCCwTR?= M3rp[GROW09? NIG2PVNKSzVyPUGuN|kh|ryP NYHhSotoOjByNk[3N|Q>
Mz-ChA-2 M3jueWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkHEglI2OCCwTR?= NHj3VG1FVVOR MY\JR|UxRTBwN{Og{txO MmGwNlAxPjZ5M{S=
ECC-1 M4LKd2tqdmG|ZTDhd5NigQ>? MWn+NVAh|ryP Mnn5SG1UVw>? MYLpcohq[mm2czDJS2YuUVJiYXP0bZZifGmxbjDifUA6QCV? NEXRTZAzOTJ7NUOzOS=>
Ishikawa M3vPbWtqdmG|ZTDhd5NigQ>? NHuxVFV,OTBizszN NHixdoNFVVOR MonRbY5pcWKrdIOgTWdHNUmUIHHjeIl3[XSrb36gZpkhQTNn M4TMc|IyOjl3M{O1
USPC-1 MWDLbY5ie2ViYYPzZZk> Mm[5glExKM7:TR?= M1PQcmROW09? M3HXSIlvcGmkaYTzJGlITi2LUjDhZ5RqfmG2aX;uJIJ6KDFyMDW= NILHZ|kzOTJ7NUOzOS=>
USPC-2 NGrO[oJMcW6jc3WgZZN{[Xl? NHrHRll,OTBizszN M1zHT2ROW09? MXzpcohq[mm2czDJS2YuUVJiYXP0bZZifGmxbjDifUA6PiV? MUCyNVI6PTN|NR?=
ECC-1 NGL0bo1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnftglExKM7:TR?= M1T2d2ROW09? Monm[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=> NVjWe4R1OjF{OUWzN|U>
Ishikawa NV60OoZrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGPLSW1,OTBizszN NGfMUGxFVVOR M{D0dIRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> NXvSVItZOjF{OUWzN|U>
USPC-1 MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4fF[Z4yOCEQvF2= M{jiTGROW09? MUfk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;u MlvnNlEzQTV|M{W=
USPC-2 M3fFXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWHRXHZihjFyIN88US=> MoDGSG1UVw>? NGLxTYJl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v MnL0NlEzQTV|M{W=

... Click to View More Cell Line Experimental Data

In vivo NVP-AEW541 (50 mg/kg, p.o.) results in abrogation of basal and IGF-I-induced receptor, and PKB and MAPK phosphorylation, with T/C value of 14% in the NWT-21 tumor xenograft. [1] NVP-AEW541 (50 mg/kg) causes tumor shrinkage in both HTLA-230 and SK-N-BE2c xenografts, without signs of systemic toxicity. NVP-AEW541 could inhibit tumor invasion both in Matrigel-coated chambers and in HTLA-230 xenografts. [3]

Protocol

Kinase Assay:[1]
- Collapse

In vitro kinase assays:

NVP-AEW541 is dissolved in DMSO (10 mM) and stored at -20 °C. Dilutions are freshly made in DMSO/water 1:1. The final concentration of DMSO in the enzyme assays is <0.5 %. The protein kinase assays are carried out in 96-well plates at RT and terminated by the addition of 20 μL of 125 mM EDTA. Subsequently, 30 μL (c-Abl, c-Src, IGF-1R) of the reaction mixture are transferred onto Immobilon-PVDF presoaked for 5 min with methanol, rinsed with water, then soaked for 5 min with 0.5 % H3PO4 and mounted on vacuum manifold. After spotting all samples, vacuum is connected and each well rinsed with 200 μL 0.5 % H3PO4. Membranes are removed and washed 4× on a shaker with 1.0 % H3PO4, once with ethanol. After drying, mounting in Packard TopCount 96-well frame, and adding of 10 μL/well of Microscint, membranes are counted. IC50 values are calculated by linear regression analysis of the percentage inhibition of NVP-AEW541 in duplicate, at four concentrations (usually 0.01, 0.1, 1, and 10 μM). One unit of protein kinase activity is defined as 1 nmol of 33P transferred from [γ33P]ATP to the substrate protein per minute per mg of protein at 37 °C.
Cell Research:[1]
- Collapse
  • Cell lines: MCF-7 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 72 hours
  • Method: Between 3 × 103 and 6 × 103 cells/well are seeded in 96-well plates with a total media volume of 100 μL/well. Increasing concentrations of NVP-AEW541 is added 24 hours thereafter in quadruplicate. 72 hours later, cells are fixed by addition of 25 μL/well Glutaraldehyde (20%) and incubation for 10 min at RT. Cells are then washed 2× with 200 μL/well H2O and 100 μL Methylene Blue (0.05%) is added. After incubation for 10 min at RT, cells are washed 3× with 200 μL/well H2O. 200 μL/well HCl (3%) is added, and following incubation for 30 min at RT on a plate shaker, absorbance is measured at 650 nm.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female Harlan athymic nude mice weighing 18-25 g with NWT-21 cells
  • Dosages: 20, 30, or 50 mg/kg
  • Administration: Administered via p.o. twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 88 mg/mL (200.2 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
20 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 439.55
Formula

C27H29N5O

CAS No. 475489-16-8
Storage powder
in solvent
Synonyms AEW541

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy NVP-AEW541 | NVP-AEW541 supplier | purchase NVP-AEW541 | NVP-AEW541 cost | NVP-AEW541 manufacturer | order NVP-AEW541 | NVP-AEW541 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID